L-DOPA-Induced Dyskinesia in Parkinson's Disease

Parkinson’s disease is characterised by progressive loss of nigrostriatal dopaminergic neurons, leading to motor symptoms such as bradykinesia, rigidity and tremor. Levodopa (L-DOPA) remains the most effective symptomatic therapy, yet chronic and intermittent administration commonly gives rise to L-DOPA-induced dyskinesia (LID) – involuntary, hyperkinetic movements that significantly impair quality of life. At the cellular level, LID reflects maladaptive plasticity in striatal medium spiny neurons, particularly sensitisation of dopamine D1 receptors that drives excessive cAMP/protein kinase A signalling, aberrant activation of extracellular signal-regulated kinases and dysregulated gene transcription. Contributing factors include altered glutamatergic transmission, ectopic dopamine release from serotonergic neurons, and changes in neurovascular function. Clinically, dyskinesia severity correlates with disease duration, levodopa dose and pattern of administration. Current efforts aim to refine drug regimens, add adjunctive therapies and target intracellular pathways or non-dopaminergic systems, with the goal of preserving motor benefit while preventing or reducing dyskinetic complications.

Research from Nature Portfolio

Recent studies have harnessed advanced imaging and molecular interventions to reveal new insights into LID mechanisms and potential treatments. One investigation using longitudinal two-photon microscopy demonstrated that intermittent L-DOPA dosing induces exaggerated dendritic spine remodelling on direct pathway projection neurons; pharmacological inhibition of actin-remodelling proteins in these cells reduced dyskinetic severity in rodent models. A gene-therapy approach targeting serotonergic neurons with an engineered enzyme stabilised synaptic dopamine release, preventing pulsatile receptor overstimulation and markedly attenuating dyskinesia without diminishing antiparkinsonian efficacy. Another report introduced a novel PET ligand for microglial activation, identifying distinct inflammatory signatures in motor circuits of dyskinetic subjects, suggesting that early anti-inflammatory interventions might delay or mitigate LID onset.

L-DOPA-Induced Dyskinesia in Parkinson's Disease publication trend

The graph below shows the total number of articles in l-dopa-induced dyskinesia in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Pulsatile administration: Intermittent dosing pattern of L-DOPA that leads to non-physiological fluctuations in brain dopamine levels.

Medium spiny neuron (MSN): Principal output neuron of the striatum, subdivided into D1 or D2 receptor-expressing populations governing direct and indirect pathways.

∆FosB: A stable transcription factor isoform that accumulates in neurons following repeated dopaminergic stimulation, associated with long-term synaptic changes.

Perivascular spaces (PVS): Fluid-filled channels surrounding cerebral blood vessels, whose enlargement can reflect vascular or glymphatic system alterations.

Synaptic plasticity: Activity-dependent modification of synaptic strength or structure underlying learning, adaptation and pathological states.

References

1. Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia. npj Parkinson's Disease (2024).
2. Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa‐Induced Dyskinesia. Movement Disorders (2023).
3. Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies. Cells (2022).
4. Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia. PLOS ONE (2010).
5. Signal transduction in l-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression. Journal of Neural Transmission (2018).
6. Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications. Frontiers in Neurology (2014).